ABSTRACT
The authors are investigating self-complementary adeno-associated virus (scAAV) as a vector for intra-articular gene-delivery of interleukin-1 receptor antagonist (IL-1Ra), and its therapeutic capacity in the treatment of osteoarthritis (OA). To model gene transfer on a scale proportional to the human knee, a frequent site of OA incidence, studies were focused on the joints of the equine forelimb. Using AAV2.5 capsid and equine IL-1Ra as a homologous transgene, a functional ceiling dose of â¼5 × 1012 viral genomes was previously identified, which elevated the steady state levels of eqIL-1Ra in synovial fluids by >40-fold over endogenous production for at least 6 months. Here, using an osteochondral fragmentation model of early OA, the functional capacity of scAAV.IL-1Ra gene-delivery was examined in equine joints over a period of 12 weeks. In the disease model, transgenic eqIL-1Ra expression was several fold higher than seen previously in healthy joints, and correlated directly with the severity of joint pathology at the time of treatment. Despite wide variation in expression, the steady-state eqIL-1Ra in synovial fluids exceeded that of IL-1 by >400-fold in all animals, and a consistent treatment effect was observed. This included a 30-40% reduction in lameness and â¼25% improvement in total joint pathology by both magnetic resonance imaging and arthroscopic assessments, which included reduced joint effusion and synovitis, and improved repair of the osteochondral lesion. No vector-related increase in eqIL-1Ra levels in blood or urine was noted. Cumulatively, these studies in the equine model indicate scAAV.IL-1Ra administration is reasonably safe and capable of sustained therapeutic IL-1Ra production intra-articularly in joints of human scale. This profile supports consideration for human testing in OA.
Subject(s)
Genetic Therapy , Genetic Vectors/administration & dosage , Interleukin 1 Receptor Antagonist Protein/genetics , Osteoarthritis/therapy , Animals , Dependovirus/genetics , Disease Models, Animal , Gene Transfer Techniques/adverse effects , Genetic Vectors/adverse effects , Genetic Vectors/genetics , Horses , Humans , Injections, Intra-Articular , Interleukin 1 Receptor Antagonist Protein/administration & dosage , Knee/pathology , Osteoarthritis/genetics , Osteoarthritis/pathologyABSTRACT
Toward the treatment of osteoarthritis (OA), the authors have been investigating self-complementary adeno-associated virus (scAAV) for intra-articular delivery of therapeutic gene products. As OA frequently affects weight-bearing joints, pharmacokinetic studies of scAAV gene delivery were performed in the joints of the equine forelimb to identify parameters relevant to clinical translation in humans. Using interleukin-1 receptor antagonist (IL-1Ra) as a secreted therapeutic reporter, scAAV vector plasmids containing codon-optimized cDNA for equine IL-1Ra (eqIL-1Ra) were generated, which produced eqIL-1Ra at levels 30- to 50-fold higher than the native sequence. The most efficient cDNA was packaged in AAV2.5 capsid, and following characterization in vitro, the virus was injected into the carpal and metacarpophalangeal joints of horses over a 100-fold dose range. A putative ceiling dose of 5 × 1012 viral genomes was identified that elevated the steady-state eqIL-1Ra in the synovial fluids of injected joints by >40-fold over endogenous levels and was sustained for at least 6 months. No adverse effects were seen, and eqIL-1Ra in serum and urine remained at background levels throughout. Using the 5 × 1012 viral genome dose of scAAV, and green fluorescent protein as a cytologic marker, the local and systemic distribution of vector and transduced cells following intra-articular injection scAAV.GFP were compared in healthy equine joints and in those with late-stage, naturally occurring OA. In both cases, 99.7% of the vector remained within the injected joint. Strikingly, the pathologies characteristic of OA (synovitis, osteophyte formation, and cartilage erosion) were associated with a substantial increase in transgenic expression relative to tissues in healthy joints. This was most notable in regions of articular cartilage with visible damage, where foci of brilliantly fluorescent chondrocytes were observed. Overall, these data suggest that AAV-mediated gene transfer can provide relatively safe, sustained protein drug delivery to joints of human proportions.
Subject(s)
Gene Transfer Techniques , Genetic Therapy , Interleukin 1 Receptor Antagonist Protein/genetics , Osteoarthritis/therapy , Animals , Dependovirus/genetics , Disease Models, Animal , Genetic Vectors/administration & dosage , Genetic Vectors/adverse effects , Genetic Vectors/genetics , Horses , Humans , Injections, Intra-Articular , Interleukin 1 Receptor Antagonist Protein/administration & dosage , Osteoarthritis/genetics , Osteoarthritis/pathologyABSTRACT
OBJECTIVE: To determine effects of leukotriene (LT) C(4) on ion transport across equine tracheal epithelium. Sample-Tracheal epithelium from cadavers of 24 horses considered free of respiratory tract disease. PROCEDURES: Mucosae were mounted into Ussing chambers, and short-circuit current (I(sc)) was monitored over time. Effects of LTC(4) were examined for various conditions, including addition of amiloride (10µM) to the mucosal bath solution, addition of bumetanide (10µM) to the serosal bath solution, addition of barium (1mM) to the serosal bath solution, and substitution of gluconate for chloride and HEPES for bicarbonate in bath solutions. Electrolyte transport was assessed via (22)Na and (36)Cl isotope fluxes. RESULTS: Addition of LTC(4) (50nM) to the serosal bath solution caused an increase in I(sc) for basal conditions and a larger increase after pretreatment with amiloride. The increase was negated in part by the addition of bumetanide to the serosal bath solution and further reduced by substitution of HEPES for bicarbonate in bath solutions. Remaining current was reduced to values less than those before treatment with LTC(4) by the addition of barium to the serosal solution. There was a small increase in I(sc) after the addition of amiloride and substitution of gluconate for chloride. Radioisotope flux indicated that addition of LTC(4) to the serosal bath solution increased chloride secretion and reduced sodium absorption. CONCLUSIONS AND CLINICAL RELEVANCE: LTC(4) stimulated chloride secretion through a predominately bumetanide-sensitive pathway, with a smaller contribution from a bicarbonate-dependent pathway. Thus, LTC(4) appears to be a potential mediator of airway hypersecretion in horses.
Subject(s)
Electric Conductivity , Horses/metabolism , Ion Transport , Leukotriene C4/metabolism , Trachea/metabolism , Animals , Barium/pharmacology , Bicarbonates/metabolism , Chlorides/metabolism , Epithelium/metabolism , Mucous Membrane/metabolism , Organic Chemicals/pharmacology , Patch-Clamp Techniques , Sodium/metabolismABSTRACT
OBJECTIVE: To determine the effects of a dose of caffeine (2.5 mg/kg, IV) administered to physically fit Thoroughbreds during incremental exercise testing to fatigue on a treadmill. ANIMALS: 10 conditioned Thoroughbreds. PROCEDURE: Horses were randomly assigned to receive caffeine or a control solution. Each horse received both treatments in a crossover design with a 3-week interval between treatments. Each horse was administered caffeine (2.5 mg/kg) or an equivalent amount of a control solution IV. One hour after injection, each horse performed an incremental exercise test to exhaustion. Hematologic values, heart rate, oxygen consumption, carbon dioxide production, plasma lactate concentration, urine and serum concentrations of caffeine and metabolites, and time until exhaustion were monitored. Statistical analysis was performed by use of a mixed-effects linear model. RESULTS: Significant differences in measured values when horses were treated with caffeine or the control solution were not detected. CONCLUSIONS AND CLINICAL RELEVANCE: A dose of caffeine (2.5 mg/kg, IV) appears to have no effect on any performance variable of physically fit Thoroughbreds during incremental exercise testing to fatigue.
Subject(s)
Caffeine/pharmacology , Central Nervous System Stimulants/pharmacology , Horses/physiology , Physical Conditioning, Animal/physiology , Animals , Caffeine/blood , Caffeine/urine , Carbon Dioxide/metabolism , Central Nervous System Stimulants/blood , Central Nervous System Stimulants/urine , Cross-Over Studies , Female , Heart Rate/drug effects , Heart Rate/physiology , Horses/blood , Horses/urine , Lactic Acid/blood , Male , Oxygen Consumption/drug effects , Oxygen Consumption/physiology , Random AllocationABSTRACT
Twelve clinically sound, healthy, athletically conditioned Thoroughbred horses were subjected to an incremental exercise stress test to determine the effects and period of detection of a single dose of flunixin meglumine (1.1 mg/kg by intravenous injection) in serum and urine by ELISA. Flunixin concentrations, performance, and hematologic and clinical chemical parameters were measured. All horses were rotated through four treatment groups of a Latin-square design providing for each horse to serve as its own control. Flunixin meglumine reduced prostaglandin F(1alpha) and thromboxane concentrations that had been increased by intense exercise. Performance parameters did not improve and prostaglandin concentrations did not significantly correlate with total run time. Exercise did not change the flunixin elimination profile in either serum or urine, and concentrations were found to be below the detection limit of the ELISA test within 36 hours in serum and 120 hours in urine.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Clonixin/pharmacology , Horses/physiology , Physical Conditioning, Animal/physiology , Adrenocorticotropic Hormone/blood , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/blood , Blood Glucose , Clonixin/administration & dosage , Clonixin/analogs & derivatives , Clonixin/blood , Creatinine/blood , Creatinine/urine , Dinoprostone/blood , Exercise Test/drug effects , Exercise Test/veterinary , Female , Hydrocortisone/blood , Injections, Intravenous/veterinary , Insulin/blood , Male , Oxygen Consumption/drug effects , Prostaglandins/blood , Prostaglandins F/blood , Thromboxane B2/blood , beta-Endorphin/bloodABSTRACT
Following the regimen used to treat equine protozoal myeloencephalitis, sulfadiazine (20 mg/kg) and pyrimethamine (1mg/kg) were administered orally once daily to 12 physically conditioned Thoroughbred horses for 4 consecutive days. The horses were randomly assigned to two test groups in a crossover design, with each horse serving as its own control. A stepwise exercise stress test was conducted to exhaustion. No effect on athletic performance was observed, and only marginal effects were noted in some hematologic and serochemical measurements, including decreased total white blood cell counts, red blood cell distribution width, total hemoglobin, serum sodium, and serum chloride. Serum folic acid concentration decreased significantly following sulfadiazine/pyrimethamine treatment.